Free Trial
→ $100 Trillion “AI Metal” Found in American Ghost Town (From Brownstone Research) (Ad) Free ETNB Stock Alerts

89BIO (ETNB) Financials

89BIO logo
$10.63 +0.12 (+1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$10.63 0.00 (0.00%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for 89BIO

Annual Income Statements for 89BIO

This table shows 89BIO's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -57 -99 -90 -102 -142 -367
Consolidated Net Income / (Loss)		 -57 -49 -90 -102 -142 -367
Net Income / (Loss) Continuing Operations		 -57 -99 -90 -102 -142 -367
Total Pre-Tax Income 		-57 -50 -90 -102 -138 -366
Total Operating Income		 -27 -49 -90 -102 -151 -385
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 27 99 90 102 151 385
Selling, General & Admin Expense		 5.29 13 19 21 29 40
Research & Development Expense		 21 36 70 81 122 345
Total Other Income / (Expense), net		 -31 -0.20 -0.53 0.24 13 18
Interest Expense		 - - 0.67 1.92 4.79 5.29
Other Income / (Expense), net		 -31 -0.20 0.15 2.16 18 24
Income Tax Expense		 0.22 -0.06 -0.15 0.02 3.87 0.69
Basic Earnings per Share		 ($24.49) ($3.08) ($4.48) ($2.93) ($2.00) ($3.51)
Weighted Average Basic Shares Outstanding		 2.34M 16.09M 20.10M 34.81M 71.17M 104.71M
Diluted Earnings per Share		 ($24.49) ($3.08) ($4.48) ($2.93) ($2.00) ($3.51)
Weighted Average Diluted Shares Outstanding		 2.34M 16.09M 20.10M 34.81M 71.17M 104.71M
Weighted Average Basic & Diluted Shares Outstanding		 2.34M 16.09M 20.35M 52.23M 93.50M 145.98M

Quarterly Income Statements for 89BIO

This table shows 89BIO's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -27 -25 -29 -39 -35 -40 -52 -48 -147 -120 -71
Consolidated Net Income / (Loss)		 -27 -25 -29 -38 -35 -40 -52 -48 -149 -118 -71
Net Income / (Loss) Continuing Operations		 -27 -25 -29 -38 -35 -40 -52 -48 -149 -118 -71
Total Pre-Tax Income 		-27 -25 -29 -38 -35 -36 -52 -48 -149 -118 -71
Total Operating Income		 -27 -25 -29 -42 -39 -41 -57 -53 -152 -122 -76
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 27 25 29 42 39 41 57 53 152 122 76
Selling, General & Admin Expense		 4.84 6.30 6.22 7.21 7.93 7.61 9.85 8.57 10 11 12
Research & Development Expense		 22 19 22 35 31 34 47 45 141 111 64
Total Other Income / (Expense), net		 0.24 0.78 -0.31 3.74 4.62 4.84 5.69 5.60 3.07 3.91 4.77
Interest Expense		 0.54 0.55 2.08 0.89 0.96 0.87 0.86 0.87 2.36 1.19 1.27
Interest & Investment Income		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Other Income / (Expense), net		 0.77 1.32 1.76 4.63 5.58 5.70 6.56 6.47 5.43 5.10 6.04
Income Tax Expense		 0.00 0.02 0.00 0.00 0.00 3.87 0.10 0.13 0.20 0.26 0.14
Basic Earnings per Share		 ($0.57) $0.13 ($0.54) ($0.52) ($0.45) ($0.49) ($0.54) ($0.48) ($1.39) ($1.10) ($0.49)
Weighted Average Basic Shares Outstanding		 47.25M 34.81M 53.17M 74.13M 76.34M 71.17M 95.85M 99.83M 107.08M 104.71M 146.37M
Diluted Earnings per Share		 ($0.57) $0.13 ($0.54) ($0.52) ($0.45) ($0.49) ($0.54) ($0.48) ($1.39) ($1.10) ($0.49)
Weighted Average Diluted Shares Outstanding		 47.25M 34.81M 53.17M 74.13M 76.34M 71.17M 95.85M 99.83M 107.08M 104.71M 146.37M
Weighted Average Basic & Diluted Shares Outstanding		 46.54M 52.23M 72.87M 75.48M 75.64M 93.50M 98.38M 105.91M 106.13M 145.98M 145.98M

Annual Cash Flow Statements for 89BIO

This table details how cash moves in and out of 89BIO's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 82 4.85 -46 2.80 261 -190
Net Cash From Operating Activities		 -25 -46 -77 -81 -129 -368
Net Cash From Continuing Operating Activities		 -25 -46 -77 -81 -129 -368
Net Income / (Loss) Continuing Operations		 -57 -49 -90 -102 -142 -367
Consolidated Net Income / (Loss)		 -57 -49 -90 -102 -142 -367
Depreciation Expense		 0.02 0.06 0.08 0.07 0.05 0.04
Amortization Expense		 0.00 0.50 1.48 -0.22 -5.37 -9.14
Non-Cash Adjustments To Reconcile Net Income		 31 3.81 8.68 11 18 23
Changes in Operating Assets and Liabilities, net		 0.96 -1.11 3.10 11 0.78 -15
Net Cash From Investing Activities		 -0.14 -107 7.16 -34 -123 -41
Net Cash From Continuing Investing Activities		 -0.14 -107 7.16 -34 -123 -41
Purchase of Property, Plant & Equipment		 -0.14 -0.13 -0.06 -0.01 -0.00 -0.02
Purchase of Investments		 0.00 -119 -141 -153 -341 -376
Sale and/or Maturity of Investments		 0.00 12 148 119 218 335
Net Cash From Financing Activities		 108 158 24 118 513 219
Net Cash From Continuing Financing Activities		 108 158 24 118 513 219
Repayment of Debt		 0.00 -0.16 0.00 0.00 -21 0.00
Repurchase of Common Equity		 - - - 0.00 0.00 -0.25
Issuance of Debt		 - 0.00 20 0.00 24 9.35
Issuance of Common Equity		 88 158 3.92 117 496 158
Other Financing Activities, net		 - - 0.00 1.09 14 52
Cash Interest Paid		 - 0.00 0.02 1.08 2.59 3.14

Quarterly Cash Flow Statements for 89BIO

This table details how cash moves in and out of 89BIO's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 12 -17 296 -105 6.49 64 -99 -5.36 -121 35 189
Net Cash From Operating Activities		 -15 -27 -30 -34 -30 -34 -40 -61 -145 -122 -72
Net Cash From Continuing Operating Activities		 -15 -27 -30 -34 -30 -34 -40 -61 -145 -122 -72
Net Income / (Loss) Continuing Operations		 -27 -25 -29 -38 -35 -40 -52 -48 -149 -118 -71
Consolidated Net Income / (Loss)		 -27 -25 -29 -38 -35 -40 -52 -48 -149 -118 -71
Depreciation Expense		 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 -0.24 -0.26 -0.82 -0.91 -1.87 -1.77 -2.66 -2.42 -2.31 -1.76 -1.44
Non-Cash Adjustments To Reconcile Net Income		 2.76 2.43 4.80 4.18 4.42 4.14 5.17 5.46 6.83 5.42 7.16
Changes in Operating Assets and Liabilities, net		 9.45 -4.68 -5.24 0.67 1.80 3.55 9.44 -16 -0.82 -6.90 -6.19
Net Cash From Investing Activities		 -42 -11 4.11 -102 38 -64 -80 28 -8.64 20 -7.83
Net Cash From Continuing Investing Activities		 -42 -11 4.11 -102 38 -64 -80 28 -8.64 20 -7.83
Purchase of Property, Plant & Equipment		 - -0.00 0.00 - - -0.00 0.00 - - -0.02 -0.07
Purchase of Investments		 -69 -43 -34 -147 -36 -124 -152 -78 -83 -63 -105
Sale and/or Maturity of Investments		 27 32 38 45 75 61 72 106 74 83 97
Net Cash From Financing Activities		 69 21 322 31 -1.48 162 21 28 33 136 269
Net Cash From Continuing Financing Activities		 69 21 322 31 -1.48 162 21 28 33 136 269
Repayment of Debt		 - - -21 - - - 0.00 - - - 0.00
Repurchase of Common Equity		 - - 0.00 - - - -0.25 0.14 - -0.14 0.00
Issuance of Debt		 - - 24 - - - 0.00 - 9.35 - 0.00
Issuance of Common Equity		 69 20 310 24 - 162 21 0.06 - 136 270
Other Financing Activities, net		 - 1.16 8.27 7.14 -1.48 0.02 0.22 28 24 0.08 -1.00
Cash Interest Paid		 0.30 0.37 0.54 0.66 0.72 0.68 0.68 0.69 0.69 1.08 0.81

Annual Balance Sheets for 89BIO

This table presents 89BIO's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 11 96 211 162 197 596 479
Total Current Assets		 11 95 210 162 196 594 476
Cash & Equivalents		 11 93 98 52 55 316 126
Restricted Cash		 0.02 0.03 0.03 0.03 - - 0.00
Short-Term Investments		 - 0.00 106 98 133 263 314
Inventories, net		 - - - 0.00 0.36 2.29 1.57
Prepaid Expenses		 0.06 1.97 5.55 11 7.92 15 36
Plant, Property, & Equipment, net		 0.03 0.16 0.17 0.15 0.09 0.05 0.02
Total Noncurrent Assets		 0.02 0.07 0.71 0.29 0.29 0.40 0.64
Other Noncurrent Operating Assets		 0.00 0.07 0.71 - 0.29 0.40 0.64
Total Liabilities & Shareholders' Equity		 11 96 211 162 197 596 479
Total Liabilities		 4.35 5.61 8.11 36 45 60 78
Total Current Liabilities		 4.35 5.61 8.11 20 25 30 36
Accounts Payable		 1.51 0.99 2.07 6.84 13 8.59 15
Accrued Expenses		 1.17 4.62 6.05 10 12 21 20
Other Current Liabilities		 1.67 - - 0.00 0.17 0.50 0.73
Total Noncurrent Liabilities		 0.00 0.00 0.00 17 20 30 42
Long-Term Debt		 - - 0.00 17 20 25 36
Other Noncurrent Operating Liabilities		 - - 0.00 0.03 0.19 5.56 6.04
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -16 90 203 126 152 536 401
Total Preferred & Common Equity		 -16 90 203 126 152 536 401
Total Common Equity		 -16 90 203 126 152 536 401
Common Stock		 0.12 164 326 339 467 994 1,225
Retained Earnings		 -16 -74 -123 -213 -315 -457 -825
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.01 -0.06 -0.35 0.19 0.56

Quarterly Balance Sheets for 89BIO

This table presents 89BIO's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 148 201 494 493 460 577 582 458 685
Total Current Assets		 147 200 494 492 460 575 580 456 683
Cash & Equivalents		 61 72 351 245 252 218 212 91 315
Restricted Cash		 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Short-Term Investments		 79 121 130 233 196 345 319 332 323
Inventories, net		 0.11 0.40 - 0.28 0.24 2.12 1.94 1.76 1.41
Prepaid Expenses		 7.22 6.51 13 14 11 12 48 32 44
Plant, Property, & Equipment, net		 0.12 0.11 0.08 0.07 0.06 0.04 0.03 0.02 0.09
Total Noncurrent Assets		 0.80 0.22 0.61 0.29 0.29 0.39 0.32 0.31 0.59
Other Noncurrent Operating Assets		 0.80 0.22 0.61 0.29 0.29 0.39 0.32 0.31 0.59
Total Liabilities & Shareholders' Equity		 148 201 494 493 460 577 582 458 685
Total Liabilities		 67 48 48 51 50 67 67 80 80
Total Current Liabilities		 27 34 24 26 25 38 42 39 38
Accounts Payable		 4.91 14 17 11 11 15 17 19 15
Accrued Expenses		 14 13 7.12 15 14 20 19 19 22
Other Current Liabilities		 0.10 0.17 0.17 0.17 0.18 0.70 0.76 0.74 0.75
Total Noncurrent Liabilities		 41 14 24 25 25 29 26 41 42
Long-Term Debt		 12 13 24 24 25 23 20 36 36
Other Noncurrent Operating Liabilities		 28 0.62 0.14 0.10 0.05 5.48 5.21 5.52 5.75
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 80 153 446 442 410 511 515 378 605
Total Preferred & Common Equity		 80 153 446 442 410 511 515 378 605
Total Common Equity		 80 153 446 442 410 511 515 378 605
Common Stock		 344 444 790 825 828 1,020 1,073 1,083 1,501
Retained Earnings		 -264 -291 -344 -382 -417 -509 -557 -706 -896
Accumulated Other Comprehensive Income / (Loss)		 -0.32 -0.44 -0.24 -0.59 -0.55 -0.52 -0.68 1.27 0.39

Annual Metrics And Ratios for 89BIO

This table displays calculated financial ratios and metrics derived from 89BIO's official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 14.31% -79.66% -13.86% -38.52% -166.63%
EBIT Growth		 0.00% 13.36% -80.79% -11.71% -33.41% -170.43%
NOPAT Growth		 0.00% -85.27% -81.83% -13.94% -47.88% -154.40%
Net Income Growth		 0.00% 13.79% -82.07% -13.21% -39.37% -158.16%
EPS Growth		 0.00% 87.42% -45.45% 34.60% 31.74% -75.50%
Operating Cash Flow Growth		 0.00% -81.63% -66.03% -5.61% -59.31% -184.72%
Free Cash Flow Firm Growth		 0.00% 0.00% -62.20% -3.88% -70.51% -172.14%
Invested Capital Growth		 0.00% 50.44% -235.50% -184.08% -10.12% 80.67%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -17.27% 1.05% -10.30% -28.19%
EBIT Q/Q Growth		 0.00% 0.00% -17.12% 1.69% -9.39% -29.10%
NOPAT Q/Q Growth		 0.00% 0.00% -18.01% 0.85% -11.71% -26.59%
Net Income Q/Q Growth		 0.00% 0.00% -17.94% 1.63% -12.35% -27.03%
EPS Q/Q Growth		 0.00% 0.00% 36.09% 32.80% -44.93% -21.03%
Operating Cash Flow Q/Q Growth		 0.00% -6.68% -22.71% 1.39% -5.90% -31.11%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -1.53% -1.73% -31.28%
Invested Capital Q/Q Growth		 0.00% 0.00% 37.90% 23.67% -32.03% 66.09%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.38% 99.88% 99.84% 100.02% 102.80% 100.19%
Interest Burden Percent		 100.00% 100.00% 100.75% 101.92% 103.59% 101.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -118.44% -33.80% -54.80% -73.46% -41.33% -78.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -90.26% -33.80% -54.80% -73.46% -41.33% -78.34%
Return on Equity Simple (ROE_SIMPLE)		 -63.84% -24.39% -71.55% -67.20% -26.51% -91.59%
Net Operating Profit after Tax (NOPAT)		 -19 -35 -63 -72 -106 -269
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -41.53% -10.03% -16.24% -20.33% -10.07% -20.42%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -41.61% -18.86% -61.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -57 -50 -90 -100 -134 -361
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -57 -49 -88 -100 -139 -370
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 4.03 2.39 2.10 3.90 1.58 2.07
Price to Tangible Book Value (P/TBV)		 4.03 2.39 2.10 3.90 1.58 2.07
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.15 0.13 0.05 0.09
Long-Term Debt to Equity		 0.00 0.00 0.13 0.13 0.05 0.09
Financial Leverage		 -1.04 -1.02 -1.02 -1.08 -1.05 -1.02
Leverage Ratio		 1.10 1.05 1.14 1.29 1.15 1.15
Compound Leverage Factor		 1.10 1.05 1.14 1.32 1.19 1.16
Debt to Total Capital		 0.00% 0.00% 13.35% 11.74% 4.42% 8.19%
Short-Term Debt to Total Capital		 0.00% 0.00% 1.72% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 11.63% 11.74% 4.42% 8.19%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 86.65% 88.26% 95.58% 91.81%
Debt to EBITDA		 0.00 0.00 -0.22 -0.20 -0.18 -0.10
Net Debt to EBITDA		 0.00 0.00 1.49 1.68 3.99 1.09
Long-Term Debt to EBITDA		 0.00 0.00 -0.19 -0.20 -0.18 -0.10
Debt to NOPAT		 0.00 0.00 -0.31 -0.28 -0.23 -0.13
Net Debt to NOPAT		 0.00 0.00 2.09 2.35 5.23 1.50
Long-Term Debt to NOPAT		 0.00 0.00 -0.27 -0.28 -0.23 -0.13
Altman Z-Score		 36.85 35.39 1.76 5.03 7.78 2.60
Noncontrolling Interest Sharing Ratio		 23.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 17.00 25.91 8.29 7.97 20.04 13.19
Quick Ratio		 16.64 25.22 7.71 7.64 19.55 12.18
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -36 -59 -61 -104 -284
Operating Cash Flow to CapEx		 -18,316.55% -36,701.59% -121,874.60% -1,158,428.57% -3,229,650.00% -2,452,153.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -87.29 -31.80 -21.74 -53.61
Operating Cash Flow to Interest Expense		 0.00 0.00 -113.92 -42.19 -26.95 -69.53
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -114.01 -42.19 -26.95 -69.53
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -3.42 -1.69 -5.68 -16 -18 -3.43
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.72 -3.99 -10 -1.63 14
Enterprise Value (EV)		 269 280 134 424 291 426
Market Capitalization		 363 484 265 592 845 830
Book Value per Share		 $6.52 $10.21 $6.21 $3.26 $7.09 $3.78
Tangible Book Value per Share		 $6.52 $10.21 $6.21 $3.26 $7.09 $3.78
Total Capital		 90 203 145 172 561 437
Total Debt		 0.00 0.00 19 20 25 36
Total Long-Term Debt		 0.00 0.00 17 20 25 36
Net Debt		 -93 -205 -131 -168 -554 -404
Capital Expenditures (CapEx)		 0.14 0.13 0.06 0.01 0.00 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.64 -2.57 -5.80 -17 -15 0.37
Debt-free Net Working Capital (DFNWC)		 90 202 145 171 564 440
Net Working Capital (NWC)		 90 202 142 171 564 440
Net Nonoperating Expense (NNE)		 39 15 27 30 36 98
Net Nonoperating Obligations (NNO)		 -93 -205 -132 -168 -554 -404
Total Depreciation and Amortization (D&A)		 0.02 0.56 1.56 -0.15 -5.32 -9.10
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.08) ($4.48) ($2.93) ($2.00) ($3.51)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 19.95M 20.35M 34.81M 71.17M 104.71M
Adjusted Diluted Earnings per Share		 $0.00 ($3.08) ($4.48) ($2.93) ($2.00) ($3.51)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 19.95M 20.35M 34.81M 71.17M 104.71M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.08) ($4.48) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 16.09M 20.35M 52.23M 93.50M 145.98M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -35 -63 -72 -106 -269
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 -132.93 -52.07 -27.85 -68.26
NOPAT to Interest Expense		 0.00 0.00 -93.20 -37.24 -22.08 -50.90
EBIT Less CapEx to Interest Expense		 0.00 0.00 -133.02 -52.08 -27.85 -68.26
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -93.30 -37.24 -22.08 -50.90
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.07%

Quarterly Metrics And Ratios for 89BIO

This table displays calculated financial ratios and metrics derived from 89BIO's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 4.98% 4.21% -10.52% -56.63% -34.50% -53.39% -93.60% -28.56% -317.69% -218.52% -33.60%
EBIT Growth		 7.28% 6.68% -6.38% -52.31% -28.54% -47.67% -89.53% -25.24% -333.89% -229.29% -37.76%
NOPAT Growth		 4.15% 3.35% -13.61% -70.30% -45.50% -62.47% -100.80% -26.84% -286.17% -196.09% -32.53%
Net Income Growth		 5.38% 6.41% -12.79% -53.24% -29.55% -63.54% -79.22% -24.95% -329.30% -194.16% -37.91%
EPS Growth		 59.57% 110.00% 57.14% 57.72% 21.05% -476.92% 0.00% 7.69% -208.89% -124.49% 9.26%
Operating Cash Flow Growth		 -10.15% 4.05% -23.58% -132.20% -104.93% -26.56% -32.03% -77.56% -378.77% -254.53% -80.61%
Free Cash Flow Firm Growth		 56.04% 49.26% -0.07% -326.32% -407.95% -272.89% -82.78% -0.02% -211.39% -266.53% -243.62%
Invested Capital Growth		 -131.13% -184.08% -175.11% 70.91% 36.34% -10.12% -149.90% 175.12% 24.74% 80.67% 109.77%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -8.04% 8.31% -13.51% -39.29% 7.22% -4.56% -43.27% 7.50% -201.43% 20.26% 39.91%
EBIT Q/Q Growth		 -6.69% 8.48% -11.31% -40.13% 9.95% -5.14% -42.87% 7.41% -211.96% 20.20% 40.23%
NOPAT Q/Q Growth		 -9.31% 6.21% -12.47% -47.70% 6.61% -4.73% -39.00% 6.71% -184.34% 19.70% 37.78%
Net Income Q/Q Growth		 -6.99% 8.22% -17.21% -33.14% 9.55% -15.87% -28.45% 7.18% -210.76% 20.61% 39.78%
EPS Q/Q Growth		 53.66% 122.81% -515.38% 3.70% 13.46% -8.89% -10.20% 11.11% -189.58% 20.86% 55.45%
Operating Cash Flow Q/Q Growth		 0.13% -82.90% -11.03% -14.50% 11.86% -12.95% -15.83% -53.99% -137.65% 16.36% 41.00%
Free Cash Flow Firm Q/Q Growth		 -127.26% -5.23% -80.10% -338.11% 38.82% 22.75% 11.72% -139.73% -90.46% 9.07% 17.24%
Invested Capital Q/Q Growth		 46.63% 23.67% 33.56% -7.51% -16.76% -32.03% -50.78% 132.32% -216.98% 66.09% 176.24%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.01% 100.07% 100.00% 100.00% 100.00% 110.63% 100.19% 100.28% 100.14% 100.22% 100.19%
Interest Burden Percent		 102.04% 102.27% 107.75% 102.38% 102.84% 102.44% 101.70% 101.86% 101.61% 101.02% 101.81%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -69.29% -73.46% -38.39% -45.44% -44.98% -41.33% -34.51% -36.50% -73.31% -78.34% -69.30%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,779.50% 0.00% 0.00% -11,906.48%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -69.29% -73.46% -38.39% -45.44% -44.98% -41.33% -34.51% -36.50% -73.31% -78.34% -69.30%
Return on Equity Simple (ROE_SIMPLE)		 -67.97% 0.00% -23.62% -26.84% -30.85% 0.00% -32.33% -33.91% -76.42% 0.00% -63.86%
Net Operating Profit after Tax (NOPAT)		 -19 -18 -20 -29 -28 -29 -40 -37 -106 -85 -53
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.78% -4.57% -3.15% -3.11% -2.41% -3.16% -2.33% -2.20% -10.52% -6.88% -3.18%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.32% - - - -5.14% -7.49% - - -19.56% -8.28%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 -24 -27 -37 -34 -36 -51 -47 -147 -117 -70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -24 -28 -38 -36 -37 -53 -49 -149 -119 -71
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.48 3.90 1.78 3.12 2.84 1.58 2.13 1.53 2.07 2.07 1.75
Price to Tangible Book Value (P/TBV)		 1.48 3.90 1.78 3.12 2.84 1.58 2.13 1.53 2.07 2.07 1.75
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 32.55 0.00 0.00 175.12
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.13 0.13 0.05 0.06 0.06 0.05 0.05 0.05 0.09 0.09 0.06
Long-Term Debt to Equity		 0.08 0.13 0.05 0.06 0.06 0.05 0.05 0.04 0.09 0.09 0.06
Financial Leverage		 -1.10 -1.08 -1.03 -1.10 -1.06 -1.05 -1.04 -1.00 -1.03 -1.02 -1.02
Leverage Ratio		 1.23 1.29 1.15 1.23 1.17 1.15 1.12 1.12 1.17 1.15 1.13
Compound Leverage Factor		 1.26 1.32 1.24 1.26 1.21 1.18 1.14 1.14 1.18 1.16 1.15
Debt to Total Capital		 11.40% 11.74% 5.18% 5.25% 5.67% 4.42% 4.66% 4.65% 8.59% 8.19% 5.60%
Short-Term Debt to Total Capital		 3.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.35% 0.88% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 7.53% 11.74% 5.18% 5.25% 5.67% 4.42% 4.31% 3.77% 8.59% 8.19% 5.60%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 88.60% 88.26% 94.82% 94.75% 94.33% 95.58% 95.34% 95.35% 91.41% 91.81% 94.40%
Debt to EBITDA		 -0.19 -0.20 -0.24 -0.21 -0.20 -0.18 -0.15 -0.14 -0.12 -0.10 -0.09
Net Debt to EBITDA		 1.71 1.68 4.44 3.88 3.37 3.99 3.26 2.88 1.34 1.09 1.55
Long-Term Debt to EBITDA		 -0.13 -0.20 -0.24 -0.21 -0.20 -0.18 -0.14 -0.12 -0.12 -0.10 -0.09
Debt to NOPAT		 -0.27 -0.28 -0.33 -0.28 -0.26 -0.23 -0.20 -0.19 -0.17 -0.13 -0.13
Net Debt to NOPAT		 2.41 2.35 6.17 5.26 4.47 5.23 4.27 3.78 1.83 1.50 2.14
Long-Term Debt to NOPAT		 -0.18 -0.28 -0.33 -0.28 -0.26 -0.23 -0.18 -0.15 -0.17 -0.13 -0.13
Altman Z-Score		 1.36 6.30 9.83 16.19 13.63 8.32 9.37 6.54 3.74 4.28 6.97
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.81 7.97 20.56 18.96 18.23 20.04 15.03 13.92 11.66 13.19 18.03
Quick Ratio		 5.62 7.64 20.02 18.42 17.78 19.55 14.70 12.76 10.83 12.18 16.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.93 -7.30 -13 -58 -35 -27 -24 -58 -110 -100 -83
Operating Cash Flow to CapEx		 0.00% -1,354,800.00% 0.00% 0.00% 0.00% -857,325.00% 0.00% 0.00% 0.00% -810,533.33% -99,634.72%
Free Cash Flow to Firm to Interest Expense		 -12.96 -13.39 -6.33 -64.41 -36.73 -31.42 -27.84 -65.89 -46.44 -83.74 -65.15
Operating Cash Flow to Interest Expense		 -27.69 -49.72 -14.50 -38.53 -31.66 -39.60 -46.03 -69.98 -61.54 -102.08 -56.62
Operating Cash Flow Less CapEx to Interest Expense		 -27.69 -49.72 -14.50 -38.53 -31.66 -39.60 -46.03 -69.98 -61.54 -102.09 -56.68
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -21 -16 -11 -12 -13 -18 -27 8.66 -10 -3.43 2.62
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -12 -10 -6.82 28 7.68 -1.63 -16 20 3.33 14 29
Enterprise Value (EV)		 53 424 339 927 742 291 551 282 396 426 458
Market Capitalization		 226 592 795 1,381 1,165 845 1,088 788 784 830 1,061
Book Value per Share		 $3.90 $3.26 $8.54 $6.07 $5.43 $7.09 $5.46 $5.23 $3.57 $3.78 $4.15
Tangible Book Value per Share		 $3.90 $3.26 $8.54 $6.07 $5.43 $7.09 $5.46 $5.23 $3.57 $3.78 $4.15
Total Capital		 172 172 470 466 435 561 535 540 414 437 641
Total Debt		 20 20 24 24 25 25 25 25 36 36 36
Total Long-Term Debt		 13 20 24 24 25 25 23 20 36 36 36
Net Debt		 -174 -168 -457 -454 -424 -554 -537 -506 -388 -404 -603
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -17 -11 -12 -14 -15 -24 12 -6.70 0.37 6.28
Debt-free Net Working Capital (DFNWC)		 172 171 470 466 434 564 538 543 417 440 645
Net Working Capital (NWC)		 165 171 470 466 434 564 537 538 417 440 645
Net Nonoperating Expense (NNE)		 7.88 6.85 8.87 8.90 7.18 11 12 11 43 33 18
Net Nonoperating Obligations (NNO)		 -174 -168 -457 -454 -424 -554 -537 -506 -388 -404 -603
Total Depreciation and Amortization (D&A)		 -0.22 -0.25 -0.81 -0.90 -1.86 -1.75 -2.65 -2.40 -2.30 -1.75 -1.43
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.57) $0.13 ($0.54) ($0.52) ($0.45) ($0.49) ($0.54) ($0.48) ($1.39) ($1.10) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding		 47.25M 34.81M 53.17M 74.13M 76.34M 71.17M 95.85M 99.83M 107.08M 104.71M 146.37M
Adjusted Diluted Earnings per Share		 ($0.57) $0.13 ($0.54) ($0.52) ($0.45) ($0.49) ($0.54) ($0.48) ($1.39) ($1.10) ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding		 47.25M 34.81M 53.17M 74.13M 76.34M 71.17M 95.85M 99.83M 107.08M 104.71M 146.37M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 46.54M 52.23M 72.87M 75.48M 75.64M 93.50M 98.38M 105.91M 106.13M 145.98M 145.98M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -18 -20 -29 -28 -29 -40 -37 -106 -85 -53
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -49.10 -44.11 -12.90 -41.95 -35.21 -41.00 -58.77 -53.73 -62.03 -98.16 -55.15
NOPAT to Interest Expense		 -35.38 -32.58 -9.62 -32.99 -28.72 -33.31 -46.46 -42.80 -45.03 -71.71 -41.94
EBIT Less CapEx to Interest Expense		 -49.10 -44.12 -12.90 -41.95 -35.21 -41.00 -58.77 -53.73 -62.03 -98.17 -55.20
NOPAT Less CapEx to Interest Expense		 -35.38 -32.58 -9.62 -32.99 -28.72 -33.31 -46.46 -42.80 -45.03 -71.72 -42.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.15% 0.00% 0.00% -0.07% 0.00%

Key Financial Trends

89bio reported progressing reductions in net losses and operating expenses in Q1 2025, funded by a sizeable equity raise that bolstered its cash runway. However, the company remains in R&D mode with no product revenue and continued quarterly cash burn. Below are key highlights from the latest quarter and historical trends:

  • Quarterly net loss narrowed to –$71.3 M in Q1 2025 from –$118.4 M in Q4 2024, reflecting lower operating costs
  • Research & development expense fell 42% Q/Q to $64.4 M, helping to moderate overall cash burn
  • Basic and diluted EPS improved to –$0.49 in Q1 2025, down from –$1.10 in Q4 2024
  • Raised $269.9 M in net proceeds from equity issuance during Q1 2025, boosting cash & equivalents to $315.4 M
  • Short-term investments of $323.4 M plus cash gives total liquidity of ~$638.8 M versus current liabilities of $37.9 M
  • Low leverage: long-term debt of $35.9 M and debt/equity ratio of 0.059
  • Continued zero product revenue as the company remains in clinical development
  • High R&D spend remains necessary for pipeline advancement
  • Operating cash flow was –$71.7 M in Q1 2025, dragging free cash flow to –$82.5 M
  • Shares outstanding rose to ~146.4 M in Q1 2025 from ~104.7 M in Q4 2024, diluting existing holders
07/16/25 08:47 PMAI Generated. May Contain Errors.

Frequently Asked Questions About 89BIO's Financials

When does 89BIO's financial year end?

According to the most recent income statement we have on file, 89BIO's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has 89BIO's net income changed over the last 5 years?

89BIO's net income appears to be on an upward trend, with a most recent value of -$367.08 million in 2024, rising from -$57.42 million in 2019. The previous period was -$142.19 million in 2023. See where experts think 89BIO is headed by visiting 89BIO's forecast page.

What is 89BIO's operating income?
89BIO's total operating income in 2024 was -$384.66 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $384.66 million
How has 89BIO's revenue changed over the last 5 years?

Over the last 5 years, 89BIO's total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does 89BIO have?

89BIO's total liabilities were at $77.90 million at the end of 2024, a 29.9% increase from 2023, and a 1,689.5% increase since 2018.

How much cash does 89BIO have?

In the past 6 years, 89BIO's cash and equivalents has ranged from $11.23 million in 2018 to $316.16 million in 2023, and is currently $126.06 million as of their latest financial filing in 2024.

How has 89BIO's book value per share changed over the last 5 years?

Over the last 5 years, 89BIO's book value per share changed from 6.52 in 2019 to 3.78 in 2024, a change of -42.1%.


Related Companies

This page (NASDAQ:ETNB) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...
Porter & Company | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...
Weiss Ratings | Sponsored
Post-Halving = Profit Season (Here’s How to Win It)
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
Is this secretive Asian company trying to take over Bitcoin?
A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...
Brownstone Research | Sponsored
Nvidia’s next AI move could catch traders flat-footed
Tired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...
Timothy Sykes | Sponsored